Romana Primus, MD in New London, CT - Allergy & Immunology

Romana Primus, MD is a Allergy & Immunology - Allergy physician based in New London, Connecticut. Romana Primus is licensed to practice in Connecticut (license number 030452) and her current practice location is 1 Shaws Cv, New London, Connecticut. She can be reached at her office (for appointments etc.) via phone at (860) 447-8304.

NPI number for Romana Primus is 1558367698 and her current mailing address is 58 Twin Lakes Dr, Waterford, Connecticut. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1558367698.

Contact Information

	Romana Primus, MD
	1 Shaws Cv, New London, CT 06320-4902
	(860) 447-8304
	(860) 443-8720

Physician's Profile

Full Name	Romana Primus
Gender	Female
Speciality	Allergy & Immunology - Allergy
Location	1 Shaws Cv, New London, Connecticut
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1558367698
Provider Enumeration Date: 06/23/2005
Last Update Date: 03/19/2009

Medical Identifiers

Medical identifiers for Romana Primus such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1558367698	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207KA0200X	Allergy & Immunology - Allergy	030452 (Connecticut)	Primary
208000000X	Pediatrics	030452 (Connecticut)	Secondary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Romana Primus is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Romana Primus, MD 58 Twin Lakes Dr, Waterford, CT 06385-4112 Ph: () -	Romana Primus, MD 1 Shaws Cv, New London, CT 06320-4902 Ph: (860) 447-8304

News Archive

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Emergent BioSolutions Inc. is hosting "Bioterrorism Prevention, Preparedness and Response," a forum organized for members of the North Atlantic Treaty Organization Parliamentary Assembly to raise global awareness of the importance of biopreparedness.

EFSA decision upholds years of research that shows safety of sucralose

The European Food Safety Authority decision upholds years of research on sucralose - the sweetening ingredient in the original SPLENDA Sweeteners - that shows it to be safe and does not cause cancer.

People exposed to North Dakota road materials face increase risk of developing mesothelioma

New data shows that people exposed to the mineral erionite found in the gravel of road materials in North Dakota may be at significantly increased risk of developing mesothelioma, a type of lung cancer most often associated with asbestos exposure, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Patients at risk of adverse events within 3 months after stopping certain ACS therapy

Patients who receive the anti-platelet medication clopidogrel following an acute coronary syndrome (such as heart attack) appear to be at greater risk of a heart attack or death in the first 90 days after stopping clopidogrel treatment, according to a study in the February 6 issue of JAMA: The Journal of the American Medical Association.

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

Romana Primus, MD - Allergy & Immunology in New London, CT